NCT05666310CompletedPhase 4
Muscle Impact of Treating Osteoporosis
The Impact of Osteoporosis Medications on Muscle Health in Older Adults
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
Osteosarcopenia is a geriatric musculoskeletal syndrome characterized by co-existence of osteoporosis and sarcopenia (low skeletal muscle mass, strength, and/or functional capacity). There is strong evidence of overlap between the pathophysiology of osteoporosis and sarcopenia (muscle-bone crosstalk). This research plan will further explore the relationship between bone and muscle, and provide new information about effect of osteoporosis medications on muscle health in older adults who are under treatment for osteoporosis.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 15 Dec 2022
- Start date
- 14 Feb 2023
- Primary completion date
- 5 Jan 2026
- Lead sponsor
- Nami Safai Haeri
- Diseases
- Osteoporosis
- NCT number
- NCT05666310
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 20
- From 14 Feb 2023 to the primary completion date, 5 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Those who have been on oral bisphosphonates for the past 1 year and intravenous bisphosphonates for the past 2 years prior to the study or
Other illness
- Subjects with severe liver disease or
Lab values
- Patients with a calculated creatinine clearance \< 35 ml/min or
Other
- Who have a contraindication for bisphosphonates or denosumab or
- Those who are scheduled for a tooth extraction to avoid jaw osteonecrosis or
- Men
Who the study is looking for
- Ambulatory adults age ≥65 years including those using assistive devices to maximize generalizability, if they have criteria for treating osteoporosis including:
- Osteoporosis by axial bone density (spine, hip or forearm BMD T-score ≤-2.5 SD) or
- A previous adult fragility fracture of the spine or hip or
- Would be treated based on FRAX National Osteoporosis Foundation treatment thresholds of a 10-year risk of ≥ 20% for a major osteoporotic fracture or ≥ 3% for hip fracture using femoral neck BMD.
Age in the registry: 65 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Pittsburgh Coordinator of this site? Confirm its status | Pittsburgh | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.